NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

NVO

Novo Nordisk ADR

Jun 20 • 04:00PM ET

73.77

Dollar change -0.24
Percentage change -0.32	%

Healthcare • Drug Manufacturers - General • Denmark • NYSE

Peers: LLY MRK ABBV JNJ AMGN AZN PFE SNY BMY GSK

| Held by: AVDE PPH DFIC PID APIE WINN OZEM DFAI RVER DFAX

Scroll to Statements

Index	-	P/E	21.88	EPS (ttm)	3.37	Insider Own	0.00%	Shs Outstand	3.37B	Perf Week	-8.98%
Market Cap	248.32B	Forward P/E	15.70	EPS next Y	4.70	Insider Trans	-	Shs Float	3.37B	Perf Month	8.17%
Enterprise Value	259.49B	PEG	1.17	EPS next Q	0.91	Inst Own	9.71%	Short Float	1.00%	Perf Quarter	-6.37%
Income	15.05B	P/S	5.70	EPS this Y	26.64%	Inst Trans	-3.84%	Short Ratio	3.36	Perf Half Y	-31.73%
Sales	43.59B	P/B	16.33	EPS next Y	17.37%	ROA	26.37%	Short Interest	33.67M	Perf YTD	-14.24%
Book/sh	4.52	P/C	41.28	EPS next 5Y	18.68%	ROE	87.53%	52W Range	57.00 - 148.15	Perf Year	-47.45%
Cash/sh	1.79	P/FCF	17.38	EPS past 3/5Y	25.78% 21.74%	ROIC	44.25%	52W High	-50.21%	Perf 3Y	39.02%
Dividend Est.	1.96 (2.66%)	EV/EBITDA	11.51	Sales past 3/5Y	23.46% 18.15%	Gross Margin	84.33%	52W Low	29.42%	Perf 5Y	125.67%
Dividend TTM	1.66 (2.25%)	EV/Sales	5.95	EPS Y/Y TTM	16.36%	Oper. Margin	45.11%	Volatility	1.84% 2.51%	Perf 10Y	156.90%
Dividend Ex-Date	Mar 31, 2025	Quick Ratio	0.56	Sales Y/Y TTM	22.74%	Profit Margin	34.52%	RSI (14)	52.28	Recom	2.03
Dividend Gr. 3/5Y	28.20% 21.81%	Current Ratio	0.74	EPS Q/Q	10.76%	SMA20	0.22%	Beta	0.66	Target Price	98.42
Payout	35.93%	Debt/Eq	0.86	Sales Q/Q	15.81%	SMA50	8.07%	Rel Volume	0.82	Prev Close	74.01
Employees	76302	LT Debt/Eq	0.70	Earnings	May 07 BMO	SMA200	-19.32%	Avg Volume	10.02M	Price	73.77
IPO	Apr 30, 1981	Option/Short	Yes / Yes	EPS/Sales Surpr.	8.78% 1.73%	Trades		Volume	8,199,073	Change	-0.32%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-17-25	Downgrade	BMO Capital Markets	Outperform → Market Perform	$64
Mar-13-25	Upgrade	Kepler	Hold → Buy
Mar-03-25	Downgrade	Stifel	Buy → Hold
Feb-12-25	Initiated	Morgan Stanley	Equal-Weight
Jan-06-25	Upgrade	Bernstein	Underperform → Mkt Perform
May-30-24	Initiated	Goldman	Buy	$156
Apr-12-24	Initiated	BMO Capital Markets	Outperform	$163
Jan-23-24	Initiated	Morgan Stanley	Overweight	$120
Jan-16-24	Resumed	UBS	Neutral
Dec-01-23	Initiated	Cantor Fitzgerald	Overweight	$120
Oct-02-23	Initiated	Argus	Buy	$110
Jul-14-23	Initiated	HSBC Securities	Buy
Jul-15-22	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jun-28-22	Downgrade	UBS	Neutral → Sell
Jun-27-22	Upgrade	Exane BNP Paribas	Underperform → Neutral
Jun-07-22	Upgrade	JP Morgan	Neutral → Overweight
May-31-22	Upgrade	Guggenheim	Neutral → Buy
Apr-25-22	Upgrade	Cowen	Market Perform → Outperform	$130
Apr-12-22	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Mar-16-22	Upgrade	Deutsche Bank	Hold → Buy

Show Previous Ratings

Today 09:02AM	Data on Novo Nordisk experimental weight-loss drug show mostly mild side effects (Reuters)
09:00AM	Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine (GlobeNewswire)
Jun-20-25 07:38PM	Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity with a third achieving 25% or more according to data presented at ADA (GlobeNewswire)
07:34PM	Novo Nordisks subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025 (GlobeNewswire)
12:49PM	How IBD 50's Hims & Hers Is Shaking Up The Weight-Loss Brawl (Investor's Business Daily)
10:41AM	Loading…
10:41AM	London Biotechnology Show 2025: Novo Nordisk harnesses AI/ML to accelerate drug development landscape (Pharmaceutical Technology)
09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
09:31AM	E.l.f. Beauty CEO Buys Up Smucker Stock (Barrons.com)
09:30AM	Ricks Is the King of Pharma, Thanks to Lilly's Zepbound (Barrons.com)
09:28AM	LLY vs. ABBV: Which Pharma Powerhouse is the Better Bet? (Zacks)
08:04AM	McDonald's Is Down, But Long-Term Investors Can Still Take a Bite (MarketBeat)
Jun-19-25 10:23AM	What is the Intent Behind Eli Lilly's Recent M&A Deals Spree? (Zacks)
Jun-18-25 11:45AM	Why Novo Nordisk (NVO) is a Great Dividend Stock Right Now (Zacks)
10:52AM	Can Ozempic, Wegovy Drive Further Growth for NVO in the Obesity Space? (Zacks)
10:22AM	GSK Stock Rises Almost 22% in 6 Months: Time to Buy, Sell or Hold? (Zacks)
09:50AM	Loading…
09:50AM	Here's Why Novo Nordisk (NVO) is a Strong Momentum Stock (Zacks)
09:00AM	Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
08:08AM	Exploring CVS' Health Services Segment: A Key Growth Engine for 2025? (Zacks)
07:51AM	Novo Nordisk seeks digital health partners to boost GLP-1RA weight loss outcomes (Pharmaceutical Technology)
07:45AM	Novo Nordisk Just Improved Its Weight-Management Pipeline: Is the Stock a Buy? (Motley Fool)
Jun-17-25 05:16PM	Trump's big beautiful bill: What the pharma industry is watching (Yahoo Finance Video)
01:48PM	Novo Nordisk Reclaims Top Spot in Europe by Market Value (Insider Monkey)
05:05AM	Novo Nordisk is losing Canadian patent protection on a blockbuster drug after not paying a small fee (Fortune)
Jun-16-25 06:21PM	Why Novo Nordisk Stock Sank by Nearly 4% Today (Motley Fool)
12:35PM	Novo Nordisk Stock Rises 6% in a Week: What Should Investors Do? (Zacks)
12:31PM	Nvidia (NVDA) Teams With Novo Nordisk to Advance AI Drug Discovery (GuruFocus.com)
07:04AM	3 Growth Stocks You Can Buy Right Now Without Any Hesitation (Motley Fool)
04:24AM	The story of how Novo Nordisk will lose billions because it didn't pay a couple of hundred dollars (MarketWatch)
Jun-15-25 05:47AM	Bernstein Keeps a Hold on Novo Nordisk (NVO), Sets a DKK620 Price Target (Insider Monkey)
05:23AM	Jim Cramer on Novo Nordisk: "We're Not Novo People" (Insider Monkey)
04:40AM	Loading…
Jun-14-25 04:40AM	1 Growth Stock Down 9% to Buy Right Now (Motley Fool)
Jun-13-25 12:58PM	Novo Nordisk Is Europe's Most Valuable Company-Again. Eli Lilly, Watch Out. (Barrons.com)
10:41AM	Lilly Moves Past 50-Day Average: Should You Buy the Stock Now? (Zacks)
09:08AM	NVO Stock up on Plans to Advance Obesity Candidate Amycretin (Zacks)
08:05AM	Novo, searching for a spark, plans late-stage trials for amylin drug (BioPharma Dive)
07:47AM	Company News for Jun 13, 2025 (Zacks)
07:39AM	Novo Nordisk ramps up obesity fight, advances amycretin to Phase III (Clinical Trials Arena)
05:07AM	Novo Nordisk regains crown as Europe's most valuable company (Reuters)
04:48AM	After ousting CEO, Novo Nordisk reclaims crown as largest European company (MarketWatch)
Jun-12-25 06:02PM	Why Novo Nordisk Stock Pumped Higher on Thursday (Motley Fool)
05:45PM	Why Novo Nordisk (NVO) Outpaced the Stock Market Today (Zacks)
01:22PM	Novo Nordisk plans to start late-stage trials of obesity drug amycretin next year (Reuters)
01:06PM	Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development (GlobeNewswire)
07:55AM	Novo Nordisk signs $812m research deal with Deep Apple for non-GLP-1 drugs (Pharmaceutical Technology)
07:00AM	4 Dividend Stocks to Double Up on Right Now (Motley Fool)
01:45AM	From AI to aerospace: Europes most innovative companies shaping tomorrow (Fortune)
Jun-11-25 10:40AM	Novo Nordisk, Deep Apple Launch Drug Discovery Alliance For Weight Loss Oral Therapies (Benzinga)
10:00AM	NVO Stock Gains After Parvus Asset Management Builds Stake (Zacks)
09:38AM	Can Mounjaro, Zepbound Help Lilly Maintain Dominance in Obesity Space? (Zacks)
09:32AM	Eli Lilly telehealth partners continue to sell compounded GLP-1 weight-loss drugs despite agreement not to (Yahoo Finance)
09:17AM	Nvidia Teams With Novo Nordisk to Supercharge Early-Stage Drug R&D (GuruFocus.com)
08:58AM	Novo signs $812 million weight-loss drug license deal with US biotech Deep Apple (Reuters)
03:13AM	The cheap fat jabs sending big pharma into a frenzy (The Telegraph)
Jun-10-25 08:51PM	Analyst Report: Novo Nordisk A/S (Morningstar Research) +5.13%
04:28PM	Stocks to Watch Recap: Tesla, TSMC, Novo Nordisk (The Wall Street Journal)
04:27PM	Eli Lilly telehealth deals to prevent sale of compounded GLP-1s (Yahoo Finance Video)
03:35PM	Hims & Hers stock falls after Lilly rules out partnership (Investing.com)
01:36PM	Why Novo Nordisk Stock Just Popped (Motley Fool)
11:10AM	Novo Nordisk Stock Climbs on Report of Activist Investor Parvus Building Stake (Investopedia)
11:08AM	Plug Power's Uzbekistan plant, Novo Nordisk activist investor (Yahoo Finance Video)
09:38AM	Stocks to Watch Tuesday: Tesla, TSMC, Novo Nordisk (The Wall Street Journal)
08:27AM	Weight-Loss Drugs Pose Long-Term Threat To McDonald's: Analyst (Investor's Business Daily)
08:27AM	McDonald's Stock Bitten By Big Downgrade Over Weight-Loss Drugs (Investor's Business Daily)
08:12AM	Novo Nordisk Stock Climbs on Report Parvus Asset Taking Stake (GuruFocus.com)
08:00AM	ADA 2025: Novo Nordisk highlights strong portfolio data with new semaglutide and CagriSema results, redefining possibilities in obesity and diabetes care (GlobeNewswire)
06:14AM	Analysis: Hims & Hers says its weight-loss business can grow as US market changes (Reuters)
03:33AM	2 Weight Loss Drug Stocks That Are Screaming Buys in June (Motley Fool)
Jun-09-25 06:49PM	Why Novo Nordisk Stock Eked Out a Win on Monday (Motley Fool)
04:08PM	Obesity Newcomer Metsera Enters The Ring With A Punch And A Big Stock Jump (Investor's Business Daily)
11:47AM	The Zacks Analyst Blog Highlights Oracle, Novo Nordisk, Linde, NVE and CPS Technologies (Zacks)
10:18AM	Pfizer Stock Down Almost 11% YTD: Should You Buy the Dip? (Zacks)
09:43AM	Obesity Newcomer Metsera, Up 23%, Enters The Ring With A Punch (Investor's Business Daily)
08:11AM	Eli Lilly's Obesity Drug Success Spurs Japanese Biotech's Anti-Muscle-Wasting Combo Therapy (Benzinga)
04:00AM	The biggest obesity deals of 2025 so far (Pharma Voice)
Jun-07-25 08:44AM	With Novo Nordisk's CEO Out, Wall Street Wants an American Leader (MarketBeat)
Jun-06-25 04:16PM	Challenges pharma companies face in push into US manufacturing (Yahoo Finance Video)
04:06PM	The Next Look At Amgen's Obesity Drug Is Coming. Here's What Investors Are Watching. (Investor's Business Daily)
02:17PM	Top Research Reports for Oracle, Novo Nordisk & Linde (Zacks)
12:38PM	Is Novo Nordisk's Next Generation Obesity Pipeline a Game Changer? (Zacks)
09:48AM	Novo Nordisk's Wegovy Tied To Increased Risk Of Rare Vision-Loss Disorder, European Regulators Say (Benzinga)
09:39AM	Was Jim Cramer Right About Novo Nordisk A/S (NVO)? (Insider Monkey)
09:00AM	Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know (Zacks)
07:26AM	EMA says Ozempic, Wegovy may cause rare eye condition (Investing.com)
04:40AM	Novo Nordisk Stock: Is It Still a Smart Buy? (Motley Fool)
Jun-05-25 08:45AM	REGN Strengthens Obesity Pipeline: Will the Move Revive the Stock? (Zacks)
04:15AM	Should You Invest $1,000 in Eli Lilly today? (Motley Fool)
02:00AM	Global Markets Are On a Tear. These Stocks in Europe and Japan Are Still Bargains. (Barrons.com)
Jun-03-25 08:17AM	Wegovy Use Among U.S. Teens Jumps 50% in 2024: Truveta (GuruFocus.com)
Jun-02-25 11:45AM	Why Novo Nordisk (NVO) is a Top Dividend Stock for Your Portfolio (Zacks)
07:12AM	Weight Loss Drug ETF (THNR) Hits New 52-Week High (Zacks)
May-30-25 07:19PM	Hims to cut 4% of workforce amid ban on weight-loss drug copies (Reuters)
05:28PM	Why the S&P 500 and Nasdaq Just Had Their Best Month Since 2023 (Investopedia)
08:00AM	2 Top Stocks to Buy With Less Than $100 (Motley Fool)
07:00AM	2 Beaten-Down Stocks to Buy on the Dip (Motley Fool)
05:00AM	How Ozempic maker Novo Nordisk fell behind Eli Lilly in the weight loss drug race (Quartz)
May-29-25 02:09PM	Meet the New Group of Weight-Loss Drugs. The Industry Is Betting Big on Amylin. (Barrons.com)
10:27AM	Novo Nordisk Is Shedding Muscle In The Weight-Loss Brawl With Eli Lilly (Investor's Business Daily)
09:31AM	AbbVie Stock Down Around 13% in 3 Months: Time to Buy the Dip? (Zacks)
May-28-25 09:00PM	How Ozempics Maker Lost Its Grip on the Obesity Market It Created (The Wall Street Journal)
11:27AM	Eli Lilly to Expand Pain Pipeline With $1B SiteOne Buyout Offer (Zacks)

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsvaerd, Denmark.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Novo Nordisk A/S	10% Owner	May 30 '25	Proposed Sale	2.14	921,897	1,972,859		May 30 08:31 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NVO

Novo Nordisk ADR

Upgrade your FINVIZ experience